The US Food and Drug Administration is working to inspect pharmaceutical manufacturing facilities more quickly with workers who are trained more quickly to accelerate a pharmaceutical manufacturing inspection program that is still recovering from the COVID-19 pandemic.
An inspection backlog that built up when investigators with the FDA’s Office of Regulatory Affairs were grounded for months during the global public health emergency has stubbornly persisted.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?